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Abstract
Background: Subtelomeric deletions of the long arm of chromosome 20 are rare, with only 11 described in the literature.
Clinical features of individuals with these microdeletions include severe limb malformations, skeletal abnormalities, growth
retardation, developmental and speech delay, mental retardation, seizures and mild, non-specific dysmorphic features.
Methodology/Principal Findings: We characterized microdeletions at 20q13.33 in six individuals referred for genetic
evaluation of developmental delay, mental retardation, and/or congenital anomalies. A comparison to previously reported
cases of 20q13.33 microdeletion shows phenotypic overlap, with clinical features that include mental retardation,
developmental delay, speech and language deficits, seizures, and behavior problems such as autistic spectrum disorder.
There does not appear to be a clinically recognizable constellation of dysmorphic features among individuals with
subtelomeric 20q microdeletions.
Conclusions/Significance: Based on genotype-phenotype correlation among individuals in this and previous studies, we
discuss several possible candidate genes for specific clinical features, including ARFGAP1, CHRNA4 and KCNQ2 and
neurodevelopmental deficits. Deletion of this region may play an important role in cognitive development.
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Introduction
Because molecular cytogenetic techniques such as microarray-
based comparative genomic hybridization (aCGH) can identify
chromosomeabnormalities in individuals with nonspecific symptoms,
such as developmental delay, without the need for clinical suspicion of
a specific disorder, these techniques have enabled a ‘‘genotype-first’’
approach to the genotype-phenotype characterization of rare
chromosome abnormalities. In such an approach, individuals with
similar genotypes, or genetic constitutions, can be identified and
examined to determine a common phenotype, or collection of clinical
features [1]. High-resolution microarray analysis also can detect small
DNA imbalances that may reveal the causative genes for specific
clinical features, which can can aid diagnosis and prognosis.
Subtelomericdeletionsofthelongarmofchromosome20arerare,
with only 11 described in the literature [2–11]. Of these previously
reported subtelomeric deletions, five individuals have been well
characterized by microarray analysis [7–9,11]. Clinical features of
individuals with these microdeletions include severe limb malforma-
tions, skeletal abnormalities, growth retardation, developmental and
speech delay, mental retardation, and seizures. There does not
appear to be a clinically recognizable constellation of dysmorphic
features among individuals with subtelomeric 20q microdeletions.
In this study we report six additional individuals with microdele-
tions at 20q13.33 and compare their phenotypes with previously
reported individualswith microdeletionsat20q13.33 microdeletion.
Among these individuals are several common clinical features
including mental retardation, developmental delay, speech and
language deficits, seizures, and behavioral problems.
Results
Molecular analysis
We identified six individuals with microdeletions at 20q13.33
ranging in size from ,561 kb to ,6.8 Mb (Table 1). Terminal
deletions were found in study subjects 1–3 and 6 and a interstitial
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12462deletions was identified in study subject 4 (Figure 1). Study subject
5 had a complex alteration with a duplication and deletion, and
study subject 6 had a complex alteration with three noncontiguous
interstitial deletions. The deletions in study subjects 3–6 were
visualized by fluorescence in situ hybridization (FISH). Parental
FISH testing for study subjects 1, 2, and 5 was normal; thus, these
deletions are apparently de novo in origin. The 20q13.33 deletion in
study subject 4 was also identified in the father.
Clinical summaries
Study subject 1 is a 9-year-old male, the first of two children
born to nonconsanguineous parents. He was born at 37 weeks
gestation by Cesarean section following a normal pregnancy. His
birth weight was in the 10–25
th percentile. Neonatally he was slow
to establish breast feeding. He was noted to have a single
generalized seizure that was not associated with fever at 6 months
of age. An EEG was normal and antiepileptic treatment was not
required. Developmental milestones were mildly delayed: he sat at
9 months, crawled at 10 months and walked at 15K months. At
18 months he was diagnosed with low muscle tone, motor
dyspraxia and global developmental delay. An MRI performed at
7 years of age showed prominent perivascular spaces bilaterally
with some cystic dilatation in the left parietal lobe. A WISC
assessment at age 9 years showed a global IQ of 40. His hearing
and vision are normal, as are his height, weight and head
circumference (HC). He did not have any dysmorphic features
(Figure 2A–B).
Study subject 2 is a 4-year-old female born at term following a
normal pregnancy. Her birth weight was in the 10
th percentile.
She is the second of three children born to healthy nonconsangui-
neous parents, with no family history of note, apart from a single
febrile convulsion in the mother. Apgars were 6 at 1 minute and 7
at 5 minutes. Seizures began at 2 weeks of life and have since
evolved into complex partial seizures, which have been ongoing
and difficult to control with medication. Development has been
globally delayed, particularly in speech and language. At 4 years of
age she has minimal expressive language, repetitive behaviors, and
minimal social interactions. She is not toilet trained and cannot
feed herself. Physical examination revealed minor dysmorphism
consisting of relatively long and mildly upslanting palpebral
fissures, mild bitemporal narrowing, and a slightly bulbous nose
(Figure 2C). Her height is at the 1st percentile, and weight and HC
are normal. Metabolic investigations were normal. An MRI scan
showed a structurally normal brain with delayed myelination in
the temporal lobes. Audiology and ophthalmology assessments
were normal.
Study subject 3 is a 3-year, 3-month-old male, the third of three
sons born to healthy nonconsanguineous parents; his two brothers
are healthy. He was born at 35 weeks gestation by emergency
Cesarean section because of a breech presentation and severe
oligohydramnios. Birth weight was ,5
th percentile. He had failure
to thrive in infancy. He has developmental delay, clubfoot, and
congenital dislocation of the right hip with chief complaint of small
lower legs and multiple congenital anomalies. At 6 months he was
treated for the hip dislocation with spica cast and surgery. Muscle
mass and tone is slightly decreased, particularly in the lower legs
with a deficit of strength. Gait shows some ballistic movements of
the lower legs. Dysmorphic features include pale complexion,
bifrontal prominence, prominent forehead, and prominent
parietal areas producing a triangular head and face. He had
epicanthal folds, down-slanting palpebral fissures, symmetric facial
hypotonia, slight hypertelorism, ptosis, low-set posteriorly rotated
ears with a thickened helix and prominent antihelix and crus,
narrow-tipped nose with decreased nasolabial folds and small alae
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Microdeletions at 20q13.33
PLoS ONE | www.plosone.org 2 August 2010 | Volume 5 | Issue 8 | e12462nasi (Figure 2D). He has significant developmental delay at the age
of 32 months, with his developmental level at 12-15 months. Both
his receptive and expressive speech are delayed, and he has only a
few words. He has motor delays, evident by a discoordinated gait.
He does not have seizures. He has a hypoplastic left nipple
although the areola is of normal size with the nipple eccentric. He
is at male stage Tanner 1 with hint of hypospadias with a
hypoplastic, flat scrotum. Both testes are palpated, the left low in
the canal and the right in the canal but moving into the scrotum
easily. His back is straight with a mildly asymmetric sacral dimple.
MRI of lumbar spine and partial MRI of entire spine were
normal. His fingers are slightly long and tapering. Lower legs have
mild shortening and thinning without apparent bony anomalies.
Feet are without arches and with a prominent heel, with the large
toes pronated and laterally angulated.
Limited information is available for study subjects 4 and 5.
Study subject 4 is a 9-year-old male referred for microarray-based
comparative genomic hybridization (aCGH) for developmental
delay, dysmorphic features, and seizure disorder. Study subject 5 is
a 23-month-old male referred for aCGH for developmental delay
and seizure disorder.
Study subject 6 was an 8-month-old female delivered at 30
weeks gestation by Caesarean section for fetal distress and
oligohydramnios. Birthweight was 1335 g (33
rd percentile), length
was 37 cm (16
th percentile), and head circumference was 27.5 cm
(26
th percentile). There were no obvious dysmorphic features other
than low-set, posteriorly rotated ears. She required respiratory
support for two days for mild surfactant deficiency, and then was
extubated and advanced on enteral feedings. Due to the
oligohydramnios without evidence of prolonged rupture of
membranes, chromosomal analysis was done that identified a
deletion in the terminal end of chromosome 20, and CGH was
sent for further evaluation. Her hospital course was complicated
by recurrent and severe thrombocytopenia of unknown etiology
requiring multiple platelet transfusions and intravenous IV IgG,
mild hydronephrosis, an echocardiogram that showed a hypo-
plastic aortic arch, perimembranous VSD, and secundum ASD,
and a head ultrasound that demonstrated asymmetry of
Figure 1. Microarray-based characterization of microdeletions at 20q13.33. (A–F) Microarray results for study subjects 1–6, respectively.
Study subject 1 was analyzed using a SNP microarray; study subjects 2–6 were analyzed using an oligonucleotide CGH-based array. For study subject
1, Copy Number Analyser for GeneChip (CNAG) version 3.0 [30] was used for the analysis. For study subjects 2–6, results were visualized using custom
aCGH analysis software (Genoglyphix; Signature Genomic Laboratories). Study subject 5 had a concurrent duplication at 20q13.33 (E). Probes are
arranged with the most proximal 20q13.31 probes on the left and the most distal 20q13.33 probes on the right. (G) Schematic representation of
deletions in study subjects 1–6 and in previously reported study subjects. Blue boxes represent genes of interest within the region.
doi:10.1371/journal.pone.0012462.g001
Microdeletions at 20q13.33
PLoS ONE | www.plosone.org 3 August 2010 | Volume 5 | Issue 8 | e12462ventricular size without associated abnormalities. On hospital day
number 22, she developed acute abdominal distention with
hematochezia, and abdominal radiographs revealed extensive
pneumatosis intestinalis with dilated loops of bowel. She
deteriorated over six hours despite full resuscitative efforts, and
demonstrated severe metabolic acidosis, hypotension, capillary
leak, poor perfusion, and respiratory failure. Surgical exploration
confirmed the diagnosis of necrotizing enterocolitis with total
necrosis of the entire bowel, and she expired shortly thereafter.
Discussion
We have identified six individuals with microdeletions at the
subtelomeric region of 20q13.33 among individuals referred for
molecular cytogenetic testing. A comparison of the clinical features
of the four individuals in our study for whom detailed information
was available with those of previously published individuals with
microdeletions of 20q13.33 identified by aCGH shows several
recurring features, including cognitive and language deficits
(Table 2). Of note, study subject 6, who had a complex alteration
with three noncontiguous interstial deletions extending 6.8 Mb,
presented with the most severe phenotype but no apparent
dysmorphic features. The severity of the phenotype may be owing
to the complexity of the rearrangement, the breakpoint locations,
and gene content. No additional reports of a similar phenotype or
early death have been described among individuals with loss of
20q13.33 [7–9].
Among individuals with 20q13.33 microdeletion, several have
seizures (study subjects 1 and 2 in this study and Beri-Deixheimer
study subject 2 [7]) and behavior problems (study subjects 2 and 3
in this study and Beri-Deixheimer study subject 2 [7]). Behavioral
problems identified in the current cohort include autistic behavior
and minimal social interactions (study subject 2) and hyperactive,
destructive behaviors (study subject 3). Behaviors noted in the
literature include poor social interaction (Beri-Deixheimer study
subject 2 [7] and Kroepfl study subject 1 [8]) and autism (Beri-
Deixheimer study subject 2 [7]). Additional behaviors reported in
individuals with microdeletions at 20q13.33 include anxiety (Bena
study subject [9]) and sleep disturbances (Beri-Deixheimer study
subject 2 [7]). As previously suggested, there does not appear to be
a clinically recognizable constellation of dysmorphic features
among individuals with subtelomeric 20q microdeletions.
Seizures have been reported for several individuals with
microdeletions encompassing 20q13.3 [2,7,12]. Among them, two
individuals with large terminal deletions of 20q presenting with
severe generalized tonic seizures [2,12]. Study subject 2 reported by
Beri-Deixheimer andcolleagues [7] suffered from a single episode of
convulsion without fever at 2 months of age. Of the current cohort,
studysubject 1 had a single seizure event at the age of6 months,and
study subject 2 had seizure onset at 2 weeks of life that progressed
into complex partial seizures. Study subjects 4 and 5 were referred
for genetic evaluation of seizures, although further clinical
information is not available for either individual. Several genes on
20q13.33 are associated with epilepsy. Mutations in KCNQ2 and
CHRNA4 have been identified in individuals with benign familial
neonatal convulsions (BFNC) and autosomal dominant nocturnal
frontal lobe epilepsy (ADNFLE), respectively [13–15]. All of the
study subjects molecularly characterized in this current report
include loss of the gene group ARFGAP1, CHRNA4, and KCNQ2.
Mouse models of Stz1 mutants, harboring a 300 kb deletion on
mouse chromosome 2 including Kcnq2, Arfgap1,a n dChrna4,
demonstrate an increased susceptibility to seizures [16]. ARFGAP1
influences cell growth, migration, and membrane traffic by sorting
cargo and driving vesicle formation at the Golgi apparatus [17].
CHRNA4 encodes alpha-4 nicotinic acetylcholine receptor subunits
and knockout mice show heightened anxiety-like behavior [16].
Potassium ion channels are involved in mammalian epilepsy, and
Kcnq2 heterozygous mutant mice demonstrate its role in the control
of neuronal excitability [14]. Study subjects 3 and 6 do not present
with seizures which suggests deletion of these genes may show
incomplete penetrance. Additional study subjects with non-
recurrent deletions encompassing ARFGAP1, CHRNA4, and KCNQ2
may provide further detailed genotype-phenotype correlations with
respect to this gene group’s role in brain development and function.
The smallest 20q13.33 microdeletion, report by Kroepfl and
colleagues [8], is a subtelomere microdeletion encompassing only
two genes, myelin transcription factor 1 (MYTI) and protein-L-
isoaspartate (D-aspartate) O-methyltransferase domain containing 2
(PCMTD2)( F i g u r e1 ) .MYT1 regulates neuronal transcription and is
involved in the proliferation and differentiation of oligodendrocytes,
cells that form the myelin sheath in the central nervous system [18].
PCMTD2 has not yet been well described and has no animal model.
Figure 2. Dysmorphic features in individuals with microdele-
tions at 20q13.33. (A,B) Study subject 1 at age 8 years. No
dysmorphic facial features were noted. (C) Study subject 2 at age 4
years. Note bitemporal narrowing, bulbous nose, and upslanting
palpebral fissures. (D) Study subject 3 at age 3 years 3 months. Note
bifrontal prominence, prominent forehead, triangular shape, mild
hypertelorism, epicanthal folds, and ptosis. (E) Hand of study subject 2.
doi:10.1371/journal.pone.0012462.g002
Microdeletions at 20q13.33
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PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e12462MYT1 is deleted in all subjects in the current study except study
subject 4 and in all recently reported individuals with microdeletions
at 20q13.33 [7–9]. Of those described, impaired psychomotor and
behavioral development have been observed [7–9]; paired with data
on the gene’s function, MYT1 is a good candidate gene for further
study to elucidate its involvement in brain function and any
associated neurological disorders influencing cognitive development.
Among the other genes with known functions in the deletion
region is SRY-box 18 (SOX18), homozygous missense mutations
and heterozygous nonsense mutations of which have been
associated with recessive and dominant forms of hypotrichosis-
lymphedema-telangiectasia syndrome [19]. SOX18 is known to
play a role in blood vessel development, hair follicle formation,
and lymphangiogenesis in mice [20–22]. The lack of features
associated with hypotrichosis-lymphedema-telangiectasia syn-
drome in this and previous reports suggests that deletions of
SOX18 may cause a milder phenotype than mutations (Table 2).
Other recognized genes within the 20q13.33 region include collagen
Type IX, alpha-3 (COL9A3), splice-site mutations of which have
been reported in families with multiple epiphyseal dysplasia
[23–25]. Clinical features observed within these families include
stiffness and pain with limited extension of joints in childhood,
with some requiring surgery in adulthood [23–25]. Subjects 2 and
6 in this study have deletions that encompass COL9A3, but the lack
of clinical features reminiscent of multiple epiphyseal dysplasia
suggests deletion of COL9A3 does not cause the syndrome.
Microdeletions at 20q13.33 are associated with a constellation
of clinical features that includes mental retardation, developmental
delay, speech and language deficits, seizure, and behavioral
problems such as autistic spectrum disorder. However, there is
no pattern of abnormalities, craniofacial, behavioral, or otherwise,
that would arouse clinical suspicion of a 20q13.33 microdeletion;
thus, molecular cytogenetic techniques such as aCGH that do not
rely on clinical suspicion of a specific disorder are useful for
diagnosis of individuals with these imbalances. The identification
of further individuals with overlapping 20q13.33 deletions will
help elucidate the roles that individual genes within this region
have on the abnormal phenotypes observed in these individuals.
Materials and Methods
Study subject ascertainment
Study subjects 1 and 2 were ascertained by Genetic Health
Services Victoria in Melbourne, Australia. Study subjects 3–6 were
ascertained by Signature Genomic Laboratories. For study subjects
1 and 2, written informed consent using a Genetic Health Services
Victoria Institutional Review Board (IRB)-approved consent form
was obtained to perform high-resolution microarray-based molec-
ular cytogenetic testing. For study subjects 3–6, written informed
consent using an IRB-Spokane-approved consent form was
obtained to perform high-resolution microarray-based molecular
cytogenetic testing.Thisstudywasapproved by the respective IRBs.
IRB-approved written consent was also obtained from study
subjects 1 and 3 to publish photographs.
Single nucleotide polymorphism (SNP) array
Study subjects 1 and 2 initially had SNP array analysis
performed using the 250K-feature Nsp Gene-Chip according to
the manufacturer’s protocols (Affymetrix, Santa Clara, CA). All
microarray data were MIAME-compliant and were deposited in
the Gene Expression Omnibus (GEO) database (http://www.ncbi.
nlm.nih.gov/geo/).
aCGH
The deletions in study subjects 3–6 were initially identified by
aCGH using various microarray platforms at Signature Genomic
Laboratories. Microarray analysis using a targeted bacterial artificial
chromosome (BAC)-based platform with 1887 BACs representing 622
loci was performed on DNA from study subject 4 as previously
described [26]. Whole-genome BAC-based microarray analysis was
originally performed on DNA from study subject 6 using a .4,600
clone custom microarray as previously described [27]. Oligonucleo-
tide-based microarray analysis was originally performed on DNA from
study subjects 3 and 5 using a custom 105K-feature whole-genome
microarray (Agilent Technologies, Santa Clara, CA) as previously
described [28]. In addition to the primary analysis, DNA samples from
study subjects 2 to 6 were re-processed using a 244K-feature whole-
genome microarray (Agilent Technologies, Santa Clara, CA) as
previously described [28]. All microarray data were MIAME-
compliant and were deposited in the Gene Expression Omnibus
(GEO) database (http://www.ncbi.nlm.nih.gov/geo/).
Fluorescence in situ hybridization (FISH)
Copy number abnormalities detected by aCGH in study subjects
3–6 were visualized by metaphase FISH using one or more BAC
cloneslocated withintheabnormal regionsasdeterminedby aCGH
[29]. Parental FISH testing was also performed.
Genoglyphix Chromosome Aberration Database
TM
(GCAD)
Study subjects 3–6 were identified by searching the Signature
Genomic Laboratories Genoglyphix Chromosome Aberration
Database (GCAD) for cases with deletions in chromosome region
20q13.33. GCAD is a database of .11,000 chromosomal
abnormalities identified in more than 40,000 individuals evaluated
by this laboratory from 2004 to the present.
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